Book a Call Today

Oligonucleotide Synthesis Market Forecast 2035 | Custom Oligos, Therapeutic Oligonucleotides, siRNA, Antisense & mRNA Synthesis for Research, Diagnostics & Pharmaceutical Manufacturing

Oligonucleotide synthesis encompasses the chemical synthesis of short single-stranded DNA and RNA sequences for research, diagnostics, and therapeutic applications, spanning custom research oligonucleotides, PCR primers, probes, guide RNAs, and therapeutic antisense, siRNA, and mRNA molecules. The global oligonucleotide synthesis market is projected to reach USD 31.3 billion by 2035 at a 18.7% CAGR, driven by therapeutic oligonucleotide pipeline expansion with ASO and siRNA drugs achieving regulatory approvals, mRNA synthesis demand for vaccines and therapeutics, guide RNA synthesis for CRISPR therapeutic applications, and diagnostic oligonucleotide demand for PCR-based infectious disease and NGS library preparation.

The oligonucleotide therapeutics pipeline — antisense oligonucleotides, siRNA, mRNA, aptamers, and CRISPR guide RNAs — is one of the most productive drug modality pipelines in pharmaceutical development, with FDA-approved ASO drugs from Ionis Pharmaceuticals and siRNA drugs from Alnylam Pharmaceuticals establishing oligonucleotide therapeutics as a validated drug class. Oligonucleotide CDMO capacity from Bachem, PolyPeptide, Ajinomoto Bio-Pharma Services, and Thermo Fisher is scaling rapidly to meet growing clinical and commercial manufacturing demand for GMP-grade therapeutic oligonucleotides.

Executive Snapshot

What is oligonucleotide synthesis?
Oligonucleotide synthesis is the chemical synthesis of short DNA or RNA sequences — typically 15–200 nucleotides in length — using solid-phase phosphoramidite chemistry, producing custom research oligos, PCR primers, probes, guide RNAs, and therapeutic antisense and siRNA molecules for research, diagnostic, and pharmaceutical applications.

What is driving oligonucleotide synthesis market growth?
Therapeutic oligonucleotide pipeline expansion with ASO and siRNA drug approvals; mRNA synthesis demand for COVID-19 vaccines and mRNA therapeutics; CRISPR guide RNA synthesis for gene editing applications; NGS library preparation oligonucleotide demand; and diagnostic PCR primer and probe demand.

What are the main oligonucleotide synthesis applications?
Research oligonucleotides — PCR primers, sequencing primers, probes — largest volume segment; therapeutic oligonucleotides — ASO, siRNA, mRNA, aptamers — highest value segment; NGS library preparation adapters and barcodes; CRISPR guide RNA synthesis; and diagnostic oligonucleotides for molecular diagnostic assays.

What is the therapeutic oligonucleotide market?
The therapeutic oligonucleotide market encompasses FDA-approved ASO drugs from Ionis (nusinersen, inotersen, viltolarsen), siRNA drugs from Alnylam (inclisiran, givosiran, patisiran), and a clinical pipeline of 100+ oligonucleotide therapeutics in clinical trials across neurology, cardiology, rare disease, and oncology indications.

Which regions lead the oligonucleotide synthesis market?
North America leads with 45%+ of global oligonucleotide synthesis revenue; Europe is the second-largest market with significant IDT (Coralville), Sigma-Aldrich/Merck, and Eurofins Genomics oligonucleotide synthesis capacity; Asia-Pacific is growing rapidly driven by BGI Genomics, Sangon Biotech, and Japan and India oligonucleotide synthesis capacity expansion.

What does the oligonucleotide synthesis market look like in 2035?
Enzymatic oligonucleotide synthesis replaces phosphoramidite chemistry for sequences above 200 nucleotides; therapeutic oligonucleotide manufacturing capacity scales to 10,000+ kg GMP-grade ASO and siRNA per year; mRNA synthesis capacity exceeds vaccine demand; and automated high-throughput guide RNA synthesis enables CRISPR screening at genome scale.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Oligonucleotide Synthesis Market

The structural forces reshaping this market — what researchers, biopharma companies, technology vendors, and investors must understand.

  • Therapeutic Oligonucleotide Pipeline Expansion Driving GMP-Grade ASO and siRNA Manufacturing Demand: 100+ oligonucleotide therapeutics in clinical development and growing FDA and EMA approvals for ASO and siRNA drugs from Ionis Pharmaceuticals and Alnylam Pharmaceuticals are driving GMP oligonucleotide therapeutic manufacturing demand as pharmaceutical companies and CDMOs including Bachem, Ajinomoto Bio-Pharma Services, and Thermo Fisher scale GMP solid-phase synthesis capacity for clinical and commercial oligonucleotide drug supply.
  • mRNA Synthesis Demand for COVID-19 Vaccines and mRNA Therapeutics Driving Scale-Up Investment: BioNTech and Moderna mRNA vaccine manufacturing and the expanding mRNA therapeutic pipeline for cancer vaccines, rare disease, and cardiometabolic applications are driving mRNA synthesis and manufacturing scale-up as enzymatic mRNA synthesis and in vitro transcription platform capacity at Thermo Fisher, Trilink Biotechnologies, and mRNA CDMO facilities scales to meet vaccine and therapeutic mRNA demand.
  • CRISPR Guide RNA Synthesis Demand Growing with Gene Editing Clinical Pipeline Expansion: CRISPR/Cas9 and base editing therapeutic pipeline expansion at Vertex, CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics requiring high-quality GMP guide RNA synthesis is driving guide RNA synthesis demand as oligonucleotide manufacturers develop GMP-grade sgRNA, pegRNA, and base editing guide RNA synthesis capabilities for clinical CRISPR therapeutic manufacturing.
  • NGS Library Preparation Oligonucleotide Demand Growing with Clinical and Research Sequencing Volume: Growing NGS sequencing volume for clinical oncology, rare disease diagnostics, and population genomics is driving NGS library preparation oligonucleotide demand for custom adapter sequences, sample barcodes, and target capture probe panels used in billions of NGS library preparation reactions annually at clinical laboratories, CROs, and sequencing centres.
  • Enzymatic Oligonucleotide Synthesis Technology Development Enabling Longer Sequences Without Organic Solvents: Enzymatic oligonucleotide synthesis technologies from DNA Script, Nuclera, and Molecular Assemblies using template-independent DNA polymerases to synthesise oligonucleotides in aqueous conditions are developing enzymatic oligonucleotide synthesis capabilities enabling longer sequences (200+ nucleotides) and reduced organic solvent requirements versus phosphoramidite chemistry.
  • Diagnostic PCR Primer and Probe Demand Driven by Infectious Disease Molecular Testing Volume: High-volume molecular diagnostic PCR testing for infectious disease — respiratory viruses, STIs, HPV, and AMR pathogens — is driving sustained diagnostic oligonucleotide demand for PCR primers and probes from IDT, Thermo Fisher, and Sigma-Aldrich serving IVD manufacturers and reference laboratories globally.

Market Segmentation: Oligonucleotide Synthesis Market

By Product
  • Oligonucleotides
    • Product type
      • DNA
        • Technology
          • Column-based
          • Array-based
      • RNA
        • Technology
          • Column-based
          • Array-based
    • Type
      • Short RNA Oligos (<65 nt)
      • Long RNA Oligos (>65 nt)
      • CRISPR (sgRNA)
  • Equipment/Synthesizer
  • Reagents
  • Services
    • DNA
      • Custom Oligo Synthesis Services
        • 25 nmol
        • 50 nmol
        • 200 nmol
        • 1000 nmol
        • 10000 nmol
      • Modification Services
      • Purification Services
    • RNA
      • Custom Oligo Synthesis Services
        • 25 nmol
        • 100 nmol
        • 1000 nmol
        • 10000 nmol
      • Modification Services
      • Purification Services
By Application
  • PCR Primers
  • PCR Assays & Panels
  • Sequencing
  • DNA Microarrays
  • Fluorescence In Situ Hybridization (FISH)
  • Antisense Oligonucleotides
  • Other Applications
By End User
  • Academic Research Institutes
  • Pharmaceutical & biotechnology companies
  • Diagnostic Laboratories
  • Hospitals
  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)
  • Other End-Use
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, 
    Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Oligonucleotide Synthesis Market

  1. Therapeutic Oligonucleotide Pipeline Expansion Driving GMP Manufacturing Capacity Scale-Up at CDMOs: 100+ oligonucleotide therapeutics in clinical development and growing FDA/EMA approvals drive GMP oligonucleotide manufacturing demand as CDMOs including Bachem, Ajinomoto Bio-Pharma Services, and Thermo Fisher scale GMP solid-phase synthesis capacity for clinical and commercial ASO and siRNA drug supply.
  2. mRNA Synthesis and Manufacturing Scale-Up Driven by COVID-19 Vaccines and mRNA Therapeutic Pipeline: BioNTech and Moderna mRNA vaccine manufacturing and the expanding mRNA therapeutic pipeline drive mRNA synthesis scale-up as enzymatic mRNA synthesis and in vitro transcription platform capacity scales at Thermo Fisher, Trilink Biotechnologies, and mRNA CDMO facilities.
  3. CRISPR Guide RNA Synthesis Demand Growing with Gene Editing Clinical Pipeline at Vertex, CRISPR Therapeutics, Editas: CRISPR/Cas9 and base editing therapeutic pipeline expansion requiring high-quality GMP guide RNA drives guide RNA synthesis demand as oligonucleotide manufacturers develop GMP-grade sgRNA and pegRNA synthesis capabilities for clinical CRISPR therapeutic manufacturing.
  4. NGS Library Preparation Oligonucleotide Demand Growing with Clinical and Research Sequencing Volume: Growing NGS sequencing volume for clinical oncology and population genomics drives NGS library preparation oligonucleotide demand for custom adapter sequences, sample barcodes, and target capture probe panels used in billions of NGS library preparation reactions annually.
  5. Enzymatic Oligonucleotide Synthesis Enabling Longer Sequences and Greener Chemistry Versus Phosphoramidite: Enzymatic oligonucleotide synthesis technologies from DNA Script, Nuclera, and Molecular Assemblies using template-independent DNA polymerases drive enzymatic oligonucleotide synthesis development enabling longer sequences and reduced organic solvent requirements versus phosphoramidite chemistry.
  6. Asia-Pacific Oligonucleotide Synthesis Market Growing at 15%+ Annually Driven by China and India Capacity Expansion: BGI Genomics, Sangon Biotech, and Indian oligonucleotide synthesis capacity expansion at Agilent and Thermo Fisher India sites are driving Asia-Pacific oligonucleotide synthesis growth at 15%+ annually serving regional research, diagnostic, and pharmaceutical manufacturing customers.

Regional Outlook: Oligonucleotide Synthesis Market

  • North America: North America leads the oligonucleotide synthesis market with 45%+ of global revenue, driven by IDT, Thermo Fisher, Ionis Pharmaceuticals, and Alnylam Pharmaceuticals — IDT, Thermo Fisher Scientific, MilliporeSigma, and Bachem are the dominant North American oligonucleotide synthesis vendors.
  • Europe: Europe is the second-largest oligonucleotide synthesis market, driven by Merck KGaA/Sigma-Aldrich, Bachem, and Eurofins Genomics oligonucleotide synthesis capacity — Merck KGaA, Bachem, Eurofins Genomics, and Ajinomoto Bio-Pharma are the leading European oligonucleotide synthesis vendors.
  • Asia-Pacific: Asia-Pacific is the fastest-growing oligonucleotide synthesis market, driven by China Sangon Biotech, BGI Genomics, and Japan and India capacity expansion — Sangon Biotech, BGI Genomics, Fasmac, and GeneDesign are the leading Asia-Pacific oligonucleotide synthesis vendors.
  • Latin America: Latin America is a growing oligonucleotide synthesis market driven by Brazil and Mexico research and diagnostic oligonucleotide demand — IDT, Thermo Fisher, and regional distributors serve Latin American oligonucleotide synthesis buyers.
  • Middle East: The Middle East is an emerging oligonucleotide synthesis market driven by UAE and Saudi Arabia research and clinical diagnostics demand — IDT, Thermo Fisher, and regional distributors serve Middle Eastern oligonucleotide synthesis buyers.

Competitive Landscape: Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market Forecast 2035 — Key Industry Participants

  • Research Oligonucleotide Synthesis Vendors: Integrated DNA Technologies (IDT), MilliporeSigma, Thermo Fisher Scientific, and Eurofins Genomics are the leading research oligonucleotide synthesis vendors competing on synthesis throughput, price per base pair, turnaround time, modification catalogue breadth, and quality assurance for PCR primers, probes, and research oligonucleotide applications.
  • Therapeutic Oligonucleotide CDMOs: Bachem, Ajinomoto Bio-Pharma Services, Avecia Biologics, and Thermo Fisher Scientific are the leading therapeutic oligonucleotide CDMOs competing on GMP solid-phase synthesis capacity, ASO and siRNA synthesis scale, modified nucleotide chemistry expertise, ICH Q7 API compliance, and regulatory filing support for clinical and commercial oligonucleotide drug manufacturing.
  • mRNA Synthesis and IVT Platform Vendors: Thermo Fisher Scientific, TriLink BioTechnologies, Aldevron, and Evonik Health Care are the leading mRNA synthesis and in vitro transcription platform vendors competing on mRNA cap analogue quality, N1-methylpseudouridine modification incorporation, IVT yield, and GMP mRNA manufacturing scale for vaccine and therapeutic mRNA applications.
  • Enzymatic and High-Throughput DNA Synthesis Platforms: DNA Script, Nuclera, Molecular Assemblies, and Twist Bioscience are the leading enzymatic and high-throughput DNA synthesis platform vendors competing on synthesis accuracy, oligo length, aqueous synthesis conditions, high-throughput library synthesis throughput, and suitability for long-fragment gene assembly.
  • CRISPR Guide RNA Synthesis and Manufacturing Vendors: Integrated DNA Technologies (IDT), MilliporeSigma, New England Biolabs, and Synthego are the leading CRISPR guide RNA synthesis and manufacturing vendors competing on sgRNA, crRNA:tracrRNA, and pegRNA synthesis quality, chemical modification catalogue, GMP guide RNA manufacturing capability, and edit efficiency performance data.
  • Oligonucleotide Synthesis Instrument Vendors: Biosearch Technologies, Glen Research, https://www.merivac.com, and https://www.bioautomation.com are the leading oligonucleotide synthesis instrument vendors competing on synthesiser throughput, column capacity, phosphoramidite chemistry compatibility, and GMP-compliant synthesis platform design for research and pharmaceutical-grade oligonucleotide production.
  • Oligonucleotide Raw Material and Phosphoramidite Suppliers: MilliporeSigma, Glen Research, ChemGenes, and LGC Biosearch Technologies are the leading oligonucleotide raw material and phosphoramidite suppliers competing on phosphoramidite purity, modified nucleoside catalogue breadth, CPG solid support quality, and oligonucleotide synthesis raw material supply chain reliability for research and GMP oligonucleotide manufacturing.

Consultant POV

“Oligonucleotide synthesis is the manufacturing backbone of the nucleic acid therapeutics revolution. Every ASO drug from Ionis, every siRNA from Alnylam, every CRISPR therapy requires large-scale GMP oligo synthesis. The industry spent 20 years validating the biology; now the constraint is manufacturing scale. The CDMOs that build 1,000–10,000 kg GMP oligo synthesis capacity in the next five years will capture the commercial manufacturing contracts for the next generation of nucleic acid drugs.”

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report